Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Sandi Kwee, Queen's Medical Centre
ClinicalTrials.gov Identifier:
NCT00928174
First received: June 24, 2009
Last updated: November 7, 2014
Last verified: November 2014
Results First Received: October 1, 2014  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Diagnostic
Condition: Prostate Cancer
Intervention: Drug: IV administration of fluorine-18 fluorocholine followed by PET/CT imaging

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Single Arm

Fluorine-18 fluorocholine IV in conjunction with PET/CT imaging, up to 3 doses.

IV administration of fluorine-18 methylcholine followed by PET/CT imaging: Imaging intervention performed prior to and 30-75 days post a change in anti-androgen therapy.


Participant Flow:   Overall Study
    Single Arm  
STARTED     27  
COMPLETED     22 [1]
NOT COMPLETED     5  
[1] 3 withdrawn before start of participation



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Single Arm

Fluorine-18 fluorocholine IV in conjunction with PET/CT imaging, up to 3 doses.

IV administration of fluorine-18 methylcholine followed by PET/CT imaging: Imaging intervention performed prior to and 30-75 days post a change in anti-androgen therapy.


Baseline Measures
    Single Arm  
Number of Participants  
[units: participants]
  27  
Age, Customized [1]
[units: participants]
 
<40     0  
40-49 years     0  
50-59 years     1  
60-69 years     9  
70-79 years     4  
80-89 years     13  
Gender  
[units: participants]
 
Female     0  
Male     27  
Race (NIH/OMB)  
[units: participants]
 
American Indian or Alaska Native     0  
Asian     13  
Native Hawaiian or Other Pacific Islander     4  
Black or African American     0  
White     9  
More than one race     0  
Unknown or Not Reported     1  
Region of Enrollment  
[units: participants]
 
United States     27  
[1] Age (10-year groupings)



  Outcome Measures

1.  Primary:   Prostate Specific Antigen (PSA) Outcome Correspondence to Imaging Results With Fluorine-18 Fluorocholine PET/CT   [ Time Frame: Concurrent with PET Procedure ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Sandi Kwee, Principal Investigator
Organization: The Queen's Medical Center
phone: 808-691-5466
e-mail: skwee@queens.org


No publications provided


Responsible Party: Sandi Kwee, Queen's Medical Centre
ClinicalTrials.gov Identifier: NCT00928174     History of Changes
Other Study ID Numbers: RA-2009-009, R21CA139687
Study First Received: June 24, 2009
Results First Received: October 1, 2014
Last Updated: November 7, 2014
Health Authority: United States: Food and Drug Administration